V
Vir Biotechnology
Biotech & Life Sciences · San Francisco, United States · Founded 2016 · IPO 2019 Unicorn
Global footprint
Where Vir Biotechnology has talent and traffic
(4 of 479 staff)
team presence
across markets
Patent intelligence
$126M patent portfolio · 118 active families
Where Vir Biotechnology concentrates vs peers
Each axis is a top-10 topic across Vir Biotechnology and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
Vir Biotechnology's 5 investments and acquisitions.
Every disclosed deal where Vir Biotechnology appeared as a backer or acquirer, 2017–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Vir Biotechnology's capital deployment.
Where the deals concentrate by sector, stage, and decade.
02 · Portfolio market map
Vir Biotechnology's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
What the market is saying about Vir Biotechnology
An AI-synthesized read of the highest-engagement posts about Vir Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vir Biotechnology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.